Emcure Pharma

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE168P01015
NSEID: EMCURE
BSEID: 544210

INR

1,380.25

-16.35 (-1.17%)

BSENSE

Dec 16

BSE+NSE Vol: 1.08 lacs

{
  "main_header": {
    "sid": 10039308,
    "name": "Emcure Pharma",
    "stock_name": "Emcure Pharma",
    "full_name": "Emcure Pharmaceuticals Ltd",
    "name_url": "stocks-analysis/emcure-pharma",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,380.25",
    "chg": -16.35,
    "chgp": "-1.17%",
    "dir": -1,
    "prev_price": "1,396.60",
    "mcapval": "26,273.00 Cr",
    "mcap": "Small Cap",
    "scripcode": 544210,
    "symbol": "EMCURE",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE168P01015",
    "curr_date": "Dec 16",
    "curr_time": "",
    "bse_nse_vol": "1.08 lacs",
    "exc_status": "Active",
    "traded_date": "Dec 16, 2025",
    "traded_date_str": "2025 12 16",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/emcure-pharma-10039308-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Emcure Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-technical-momentum-shifts-amid-mixed-market-signals-3759607",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/EmcurePharmaceu_technicaldot_3759607.png",
        "date": "2025-12-16 08:18:40",
        "description": "Emcure Pharmaceuticals has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and mildly bearish indicators across multiple timeframes. The stock’s recent price action and technical signals suggest a cautious market stance amid broader sector dynamics."
      },
      {
        "title": "Emcure Pharmaceuticals Sees Shift in Market Assessment Amid Strong Technical and Financial Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/emcure-pharmaceuticals-upgraded-to-buy-on-strong-technical-and-financial-performance-3758406",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/EmcurePharmaceu_mojoScore_3758406.png",
        "date": "2025-12-15 08:14:12",
        "description": "Emcure Pharmaceuticals has experienced a notable revision in its market evaluation, reflecting a combination of robust technical indicators and solid financial performance. The company’s recent quarter results, alongside evolving market trends, have contributed to a fresh perspective on its investment potential within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Emcure Pharmaceuticals Sees Shift in Technical Momentum Amid Market Fluctuations",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-gains-bullish-momentum-amid-technical-upgrades-3758375",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/EmcurePharmaceu_technicaldot_3758375.png",
        "date": "2025-12-15 08:06:17",
        "description": "Emcure Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. Recent evaluation adjustments highlight a transition towards a more bullish technical trend, supported by key indicators such as MACD, moving averages, and Bollinger Bands, while some oscillators remain neutral or mildly bearish."
      },
      {
        "title": "Why is Emcure Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-emcure-pharma-fallingrising-3757880",
        "imagepath": "",
        "date": "2025-12-13 01:25:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Strong Quarterly Performance and Financial Metrics</strong></p>\n<p>Emcure Pharma’s recent quarterly results have been a key driver behind the stock’s positive momentum. The company has reported its highest net sales for the quarter at ₹2,269.82 crores, alongside a record PBDIT of ₹475.47 crores. These figures mark the fifth consecutive quarter of positive results, signalling consistent operational strength. Additionally, the declared dividend per share (DPS) stands at ₹3.00, the highest in recent periods, which may appeal to income-focused investors.</p>\n<p>Management efficiency remains a highlight, with a return on capital employed (ROCE) of 21.37%, underscoring the company’s ability to generate strong returns on its investments. Furthermore, Emcure maintains a conservative capital structur..."
      },
      {
        "title": "Emcure Pharma’s Evaluation Revised Amid Mixed Financial and Market Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/marketsmojo-downgrades-emcure-pharma-from-buy-to-hold-on-1-sep-2025-3730730",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EmcurePharma_mojoScore_3730730.png",
        "date": "2025-11-26 09:46:59",
        "description": "Emcure Pharma’s recent assessment has undergone a revision reflecting nuanced shifts across key evaluation parameters including quality, valuation, financial trends, and technical outlook. This adjustment comes amid a backdrop of steady operational performance and evolving market dynamics within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Emcure Pharmaceuticals Trades 1,634,517 Shares, Ranking Among Today's Most Active Equities",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/emcure-pharmaceuticals-trades-1634517-shares-ranking-among-todays-most-active-equities-3711316",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EmcurePharmaceu_most_active_equities_by_value_3711316.png",
        "date": "2025-11-18 10:00:32",
        "description": "Emcure Pharmaceuticals Ltd has become one of the most actively traded stocks today, with a volume of over 1.6 million shares. Despite a decline in its stock price, investor participation has increased, and the stock remains above its 200-day moving average, indicating ongoing market interest."
      },
      {
        "title": "How has been the historical performance of Emcure Pharma?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-emcure-pharma-3695832",
        "imagepath": "",
        "date": "2025-11-13 00:41:59",
        "description": "Answer:\nEmcure Pharma has shown a positive trend in its historical performance, with significant growth in net sales and profits over the past three years.\n\nBreakdown:\nIn the fiscal year ending March 2025, Emcure Pharma reported net sales of 7,896.00 Cr, an increase from 6,658.25 Cr in March 2024 and 5,985.81 Cr in March 2023. The total operating income mirrored this growth, reaching 7,896.00 Cr in March 2025. The company's total expenditure also rose to 6,421.62 Cr, up from 5,428.53 Cr in the previous year. Operating profit (PBDIT) increased to 1,541.64 Cr in March 2025, compared to 1,286.71 Cr in March 2024. Profit before tax reached 971.35 Cr, up from 727.23 Cr, and profit after tax was 707.47 Cr, an increase from 527.58 Cr in the prior year. The consolidated net profit for March 2025 was reported at 681.33 Cr, up from 498.18 Cr in March 2024. The company's earnings per share also improved, reaching 35.9..."
      },
      {
        "title": "Are Emcure Pharma latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-emcure-pharma-latest-results-good-or-bad-3693277",
        "imagepath": "",
        "date": "2025-11-12 19:36:16",
        "description": "Emcure Pharmaceuticals has reported its financial results for the quarter ended September 2025, showcasing a notable operational performance. The company achieved net sales of ₹2,269.82 crores, reflecting a sequential growth of 8.06% compared to the previous quarter. This growth is accompanied by a year-on-year revenue increase of 13.38%, indicating a robust sales trajectory. \n\nIn terms of profitability, Emcure's net profit reached ₹243.46 crores, which is a 17.64% increase from the prior quarter and a significant 25.13% rise year-on-year. The operating margin, excluding other income, expanded to 20.95%, marking the highest level in the last eight quarters. This improvement in margins suggests effective cost management and operational efficiency, which are critical in the capital-intensive pharmaceutical sector.\n\nThe company also demonstrated strong capital efficiency, with a return on equity of 15.50% and ..."
      },
      {
        "title": "Emcure Pharmaceuticals Q2 FY26: Strong Quarter Marred by Premium Valuation Concerns",
        "link": "https://www.marketsmojo.com/news/result-analysis/emcure-pharmaceuticals-q2-fy26-strong-quarter-marred-by-premium-valuation-concerns-3690801",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/EmcurePharmaceu_quaterlyResult_3690801.png",
        "date": "2025-11-11 20:19:19",
        "description": "Emcure Pharmaceuticals Ltd., a mid-sized pharmaceutical manufacturer with a market capitalisation of ₹26,706 crores, delivered a robust performance in Q2 FY26, posting consolidated net profit of ₹243.46 crores—a sequential improvement of 17.64% and a year-on-year surge of 25.13%. However, the stock declined 3.90% on November 11, 2025, trading at ₹1,371.95, as investors grappled with the company's expensive valuation multiples and concerns over long-term growth sustainability."
      }
    ],
    "total": 336,
    "sid": "10039308",
    "stock_news_url": "https://www.marketsmojo.com/news/emcure-pharmaceuticals-10039308"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "01-Dec-2025",
      "details": "Intimation of schedule of Analyst/ Investor Meeting(s)",
      "source": "BSE"
    },
    {
      "caption": "Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Regarding Search And Seizure/ Inspection Operation Conducted By The Goods & Service Tax Department Mumbai Maharashtra.",
      "datetime": "27-Nov-2025",
      "details": "Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 regarding search and seizure/ inspection operation conducted by Good & Service Tax Department Mumbai Maharashtra at offices of the Company.",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer",
      "datetime": "21-Nov-2025",
      "details": "Mr. Chetan Sharma (FCS:8352) has submitted his resignation from post of company Secretary and Compliance Officer & Key Managerial Personnel of the Company with effect from close of business hours on November 24 2025 to pursue opportunities outside the organization.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Emcure Pharmaceuticals Ltd has declared <strong>30%</strong> dividend, ex-date: 14 Aug 25",
          "dt": "2025-08-14",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Emcure Pharmaceuticals Technical Momentum Shifts Amid Mixed Market Signals

2025-12-16 08:18:40

Emcure Pharmaceuticals has experienced a nuanced shift in its technical momentum, reflecting a complex interplay of bullish and mildly bearish indicators across multiple timeframes. The stock’s recent price action and technical signals suggest a cautious market stance amid broader sector dynamics.

Emcure Pharmaceuticals Sees Shift in Market Assessment Amid Strong Technical and Financial Signals

2025-12-15 08:14:12

Emcure Pharmaceuticals has experienced a notable revision in its market evaluation, reflecting a combination of robust technical indicators and solid financial performance. The company’s recent quarter results, alongside evolving market trends, have contributed to a fresh perspective on its investment potential within the Pharmaceuticals & Biotechnology sector.

Emcure Pharmaceuticals Sees Shift in Technical Momentum Amid Market Fluctuations

2025-12-15 08:06:17

Emcure Pharmaceuticals has experienced a notable shift in its technical momentum, reflecting evolving market dynamics within the Pharmaceuticals & Biotechnology sector. Recent evaluation adjustments highlight a transition towards a more bullish technical trend, supported by key indicators such as MACD, moving averages, and Bollinger Bands, while some oscillators remain neutral or mildly bearish.

Why is Emcure Pharma falling/rising?

2025-12-13 01:25:59

Strong Quarterly Performance and Financial Metrics

Emcure Pharma’s recent quarterly results have been a key driver behind the stock’s positive momentum. The company has reported its highest net sales for the quarter at ₹2,269.82 crores, alongside a record PBDIT of ₹475.47 crores. These figures mark the fifth consecutive quarter of positive results, signalling consistent operational strength. Additionally, the declared dividend per share (DPS) stands at ₹3.00, the highest in recent periods, which may appeal to income-focused investors.

Management efficiency remains a highlight, with a return on capital employed (ROCE) of 21.37%, underscoring the company’s ability to generate strong returns on its investments. Furthermore, Emcure maintains a conservative capital structur...

Emcure Pharma’s Evaluation Revised Amid Mixed Financial and Market Signals

2025-11-26 09:46:59

Emcure Pharma’s recent assessment has undergone a revision reflecting nuanced shifts across key evaluation parameters including quality, valuation, financial trends, and technical outlook. This adjustment comes amid a backdrop of steady operational performance and evolving market dynamics within the Pharmaceuticals & Biotechnology sector.

Emcure Pharmaceuticals Trades 1,634,517 Shares, Ranking Among Today's Most Active Equities

2025-11-18 10:00:32

Emcure Pharmaceuticals Ltd has become one of the most actively traded stocks today, with a volume of over 1.6 million shares. Despite a decline in its stock price, investor participation has increased, and the stock remains above its 200-day moving average, indicating ongoing market interest.

How has been the historical performance of Emcure Pharma?

2025-11-13 00:41:59

Answer: Emcure Pharma has shown a positive trend in its historical performance, with significant growth in net sales and profits over the past three years. Breakdown: In the fiscal year ending March 2025, Emcure Pharma reported net sales of 7,896.00 Cr, an increase from 6,658.25 Cr in March 2024 and 5,985.81 Cr in March 2023. The total operating income mirrored this growth, reaching 7,896.00 Cr in March 2025. The company's total expenditure also rose to 6,421.62 Cr, up from 5,428.53 Cr in the previous year. Operating profit (PBDIT) increased to 1,541.64 Cr in March 2025, compared to 1,286.71 Cr in March 2024. Profit before tax reached 971.35 Cr, up from 727.23 Cr, and profit after tax was 707.47 Cr, an increase from 527.58 Cr in the prior year. The consolidated net profit for March 2025 was reported at 681.33 Cr, up from 498.18 Cr in March 2024. The company's earnings per share also improved, reaching 35.9...

Are Emcure Pharma latest results good or bad?

2025-11-12 19:36:16

Emcure Pharmaceuticals has reported its financial results for the quarter ended September 2025, showcasing a notable operational performance. The company achieved net sales of ₹2,269.82 crores, reflecting a sequential growth of 8.06% compared to the previous quarter. This growth is accompanied by a year-on-year revenue increase of 13.38%, indicating a robust sales trajectory. In terms of profitability, Emcure's net profit reached ₹243.46 crores, which is a 17.64% increase from the prior quarter and a significant 25.13% rise year-on-year. The operating margin, excluding other income, expanded to 20.95%, marking the highest level in the last eight quarters. This improvement in margins suggests effective cost management and operational efficiency, which are critical in the capital-intensive pharmaceutical sector. The company also demonstrated strong capital efficiency, with a return on equity of 15.50% and ...

Emcure Pharmaceuticals Q2 FY26: Strong Quarter Marred by Premium Valuation Concerns

2025-11-11 20:19:19

Emcure Pharmaceuticals Ltd., a mid-sized pharmaceutical manufacturer with a market capitalisation of ₹26,706 crores, delivered a robust performance in Q2 FY26, posting consolidated net profit of ₹243.46 crores—a sequential improvement of 17.64% and a year-on-year surge of 25.13%. However, the stock declined 3.90% on November 11, 2025, trading at ₹1,371.95, as investors grappled with the company's expensive valuation multiples and concerns over long-term growth sustainability.

View All News

Announcement

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

01-Dec-2025 | Source : BSE

Intimation of schedule of Analyst/ Investor Meeting(s)

Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 Regarding Search And Seizure/ Inspection Operation Conducted By The Goods & Service Tax Department Mumbai Maharashtra.

27-Nov-2025 | Source : BSE

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 regarding search and seizure/ inspection operation conducted by Good & Service Tax Department Mumbai Maharashtra at offices of the Company.

Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance Officer

21-Nov-2025 | Source : BSE

Mr. Chetan Sharma (FCS:8352) has submitted his resignation from post of company Secretary and Compliance Officer & Key Managerial Personnel of the Company with effect from close of business hours on November 24 2025 to pursue opportunities outside the organization.